Skip to main content

Table 5 HBsAg prevalence derived from studies among general migrant populations resident in Europe compared to in-country prevalence estimates derived from worldwide systematic reviews

From: Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries

Country

Migrants

In-country of origin

Comparison

N tested

Prevalence

95% CI

Reference

Prevalence

95% CI

Reference

Afghanistan

293

2.1

0.8–4.4

[30]

10.5

5.9–15.1

[20]

Lower

Albania

504a

11.7

9.0–14.8

[31]

9.0

8.1–9.8

[9]

Higher

Bangladesh

934

1.3

0.7–2.2

[32, 33]

4.8

4.0–5.6

[20]

Lower

Chinab

1319

9.4

7.9–11.1

[33, 34]

10.2 c

9.4–11.2

[20]

Comparable

Dutch Antilles

38

2.6

0.1–13.8

[35]

4.5d

2.5–6.6

[20]

Comparable

Egypt

465

1.1

0.4–2.5

[36]

4.2 c

1.9–6.5

[20]

Lower

Former USSR

675

4.7

3.3–6.6

[30, 37]

3.8

2.7–4.9

[20]

Comparable

India

1334

0.1

0–0.4

[32, 38]

3.2

2.9–3.6

[20]

Lower

Iran

153

0.7

0.1–2.5

[30]

3.1

2.7–3.5

[20]

Lower

Iraq

290

0.7

0–3.6

[30]

1.3

0–2.9

[20]

Comparable

Morocco

305

0.3

0–1.8

[35, 39]

1.8

1.5–5.9

[20, 22]

Lower

Pakistan

3786

1.6

1.2–2.1

[32, 33, 38, 40]

4.2

3.6–4.8

[20]

Lower

Somalia

317

7.3

4.6–10.7

[41]

12.4

8.9–15.9

[20]

Lower

Suriname

56

0

0–6.4

[35]

4.5d

2.5–6.6

[20]

Lower

Turkey

902

3.7

2.5–5.1

[30, 35, 39]

4.3c

3.7–4.9

[20]

Comparable

Vietnam

149

10.7

6.3–16.9

[30, 33]

12.5

11.5–13.5

[20]

Lower

  1. Notes:
  2. aage range of participants 10–23 years
  3. bincluding Hong Kong
  4. cstatistically significant decline over time reported therefore the latest estimate (from year 2000 onwards) selected
  5. dregional estimate for Caribbean only